Known targets — ChEMBL curated mechanism
ADRA2AADRA2BADRA2CADRB2AGTR1AVPR1AAVPR1BAVPR2BDKRB2CALCRCHRNA3CHRNB4ESR1ESR2GHSRGNRHRGSC1HSPA8MALT1MC1RMC4RNOS1NOS2NOS3OPRK1OXTRRAMP1RAMP2RAMP3SCN5ASSTR1SSTR2SSTR3SSTR4SSTR5dacAdacBdacCfolPftsImrcAmrcBmrdArplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Trolamine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.35 |
| ▸ | FFAR3 | O14843 | 2/20 | 0.44 |
| ▸ | LCK | P06239 | 1/20 | 0.44 |
| ▸ | FYN | P06241 | 1/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | EYA2 | O00167 | 1/20 | 0.36 |
| ▸ | APP | P05067 | 1/20 | 0.36 |
| ▸ | ACE | P12821 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 3/20 | 0.35 |
| ▸ | TSHR | P16473 | 3/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | DRD1 | P21728 | 1/20 | 0.35 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trolamine SCHEMBL28327104 | 1.00 | FFAR3 (0.44) | FFAR3LCKFYNALOX15MAPT | |
| Trolamine SCHEMBL135684 | 1.00 | FFAR3 (0.44) | FFAR3LCKFYNALOX15MAPT | |
| Trolamine SCHEMBL28634962 | 1.00 | FFAR3 (0.44) | FFAR3LCKFYNALOX15MAPT | |
| Trolamine SCHEMBL29400146 | 1.00 | FFAR3 (0.44) | FFAR3LCKFYNALOX15MAPT | |
| Trolamine SCHEMBL11411163 | 0.97 | FFAR3 (0.41) | FFAR3LCKFYNALOX15MAPT | |
| Trolamine SCHEMBL27977489 | 0.97 | FFAR3 (0.41) | FFAR3LCKFYNALOX15MAPT | |
| Trolamine SCHEMBL3631034 | 0.97 | FFAR3 (0.41) | FFAR3LCKFYNALOX15MAPT | |
| Trolamine SCHEMBL30722438 | 0.97 | FFAR3 (0.41) | FFAR3LCKFYNALOX15MAPT | |
| Trolamine SCHEMBL18317908 | 0.94 | ALOX15 (0.39) | FFAR3LCKFYNALOX15MAPT | |
| Trolamine SCHEMBL28456833 | 0.90 | KDM4E (0.44) | ALOX15MAPTKDM4ESMN1; SMN2TDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 658 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3692981-B1 | TOPICAL COMPOSITION FOR USE IN THE TREATMENT OF PSORIASIS | CHEM CURE ASS LLC (US) | 2022-05-04 | — | — | EP | claimed |
| US-11260063-B2 | Method and compositions for treating psoriasis | CHEM-CURE ASSOCIATES LLC (US) | 2022-03-01 | — | — | US | claimed |
| EP-3692981-A1 | TOPICAL COMPOSITION FOR USE IN THE TREATMENT OF PSORIASIS | Anaplasi Pharmaceuticals LLC (US) | 2020-08-12 | — | — | EP | claimed |
| US-20200129529-A1 | METHOD AND COMPOSITIONS FOR TREATING PSORIASIS | ANAPLASI Pharmaceuticals, LLC (US) | 2020-04-30 | — | — | US | claimed |
| EP-3305299-B1 | METHOD AND COMPOSITIONS FOR TREATING PSORIASIS | ANAPLASI PHARMACEUTICALS LLC (US) | 2020-04-29 | — | — | EP | claimed |
| US-10124013-B2 | Methods and compositions for treating psoriasis | ANAPLASI Pharmaceuticals, LLC (US) | 2018-11-13 | — | — | US | claimed |
| EP-3305299-A1 | METHOD AND COMPOSITIONS FOR TREATING PSORIASIS | Anaplasi Pharmaceuticals LLC (US) | 2018-04-11 | — | — | EP | claimed |
| EP-2906199-B1 | METHOD AND COMPOSITIONS FOR TREATING PSORIASIS | ANAPLASI PHARMACEUTICALS LLC (US) | 2018-01-03 | — | — | EP | claimed |
| US-20170296557-A1 | Methods and Compositions for Treating Psoriasis | ANAPLASI PHARMACEUTICALS LLC (US) | 2017-10-19 | — | — | US | claimed |
| US-9717741-B2 | Method and compositions for treating psoriasis | ANAPLASI PHARMACEUTICALS LLC (US) | 2017-08-01 | — | — | US | claimed |
| EP-1264212-B1 | ELEMENTS FOR FORMING PRINT-OUT IMAGES | DU PONT (US) | 2009-02-18 | — | — | EP | claimed |
| US-6869755-B2 | Elements for forming print-out images | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2005-03-22 | — | — | US | claimed |
| EP-1264212-A2 | ELEMENTS FOR FORMING PRINT-OUT IMAGES | E. I. du Pont de Nemours and Company (US) | 2002-12-11 | — | — | EP | claimed |
| US-20020146649-A1 | Elements for forming print-out images | E. I. DU PONT DE NEMOURS AND COMPANY | 2002-10-10 | — | — | US | claimed |
| WO-2001067175-A2 | ELEMENTS FOR FORMING PRINT-OUT IMAGES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2001-09-13 | — | — | WO | claimed |
| US-5403426-A | Surface treatment | HERCULES INCORPORATED (US) | 1995-04-04 | — | — | US | claimed |
| US-4252531-A | ANIONIC DYES IN A LIQUOR OF A CARBOXYLIC ACID ESTER HAVING A TERTIARY AMINE GROUP | BASF AKTIENGESELLSCHAFT (DE) | 1981-02-24 | — | — | US | claimed |
| JP-56102845-A | — | — | None | — | — | JP | disclosed |
| US-4029506-A | Universal product code marking composition containing a photosensitive dye former, a pigment and a binder and the use thereof | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-06-14 | — | — | US | disclosed |
| US-4017313-A | Photosensitive composition containing a leuco dye, a photosensitizer, an aromatic aldehyde and a secondary or tertiary amine and the use thereof in a direct-print process | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 1977-04-12 | — | — | US | disclosed |